Patents by Inventor Marlene Asklund

Marlene Asklund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER
    Publication number: 20120322848
    Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstsCsCsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.
    Type: Application
    Filed: April 10, 2012
    Publication date: December 20, 2012
    Applicant: Santaris Pharma A/S
    Inventors: Christoph Rosenbohm, Lene S. Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens B. Hansen, Marlene Asklund
  • LNA oligonucleotides and the treatment of cancer
    Patent number: 8173428
    Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumor development in vivo.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 8, 2012
    Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.
    Inventors: Christoph Rosenbohm, Lene Sonderbye Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens Bo Hansen, Marlene Asklund
  • LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER
    Publication number: 20090181914
    Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx)(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.
    Type: Application
    Filed: October 10, 2008
    Publication date: July 16, 2009
    Applicants: SANTARIS PHARMA A/S, ENZON PHARMACEUTICALS, INC.
    Inventors: CHRISTOPH ROSENBOHM, LENE S. KJAERULFF, MAJKEN WESTERGAARD, MARGIT WISSENBACH, JENS B. HANSEN, MARLENE ASKLUND
  • LNA oligonucleotides and the treatment of cancer
    Publication number: 20060154888
    Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo.
    Type: Application
    Filed: November 9, 2005
    Publication date: July 13, 2006
    Applicant: Santaris Pharma A/S
    Inventors: Christoph Rosenbohm, Lene Kjaerulff, Majken Westergaard, Margit Wissenbach, Jens Hansen, Marlene Asklund